BioXcel Therapeutics, Inc. (BTAI) Dividend History

BioXcel Therapeutics, Inc. (BTAI) is a biotechnology company focused on the development and commercialization of artificial intelligence-driven therapies for neuroscience and immuno-oncology indications. The company utilizes its proprietary platform to identify and develop innovative drug candidates, aiming to address unmet medical needs in areas such as acute neuropsychiatric disorders and cancer.

555 Long Wharf Drive, New Haven, CT, 06511
Phone: 203-643-8060
Website: https://www.bioxceltherapeutics.com

Dividend History

BioXcel Therapeutics, Inc. currently does not pay dividends

Company News

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

BioXcel Therapeutics was granted an extension by Nasdaq to regain compliance with listing requirements. The company is focused on advancing its SERENITY At-Home Phase 3 trial for BXCL501, an investigational treatment for agitation associated with bipolar disorders or schizophrenia.

GlobeNewswire Inc.
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight

The substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.

GlobeNewswire Inc.

Featured Companies: ADIL CMND INDV
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics has strengthened its cash position to $35 million, which will support the advancement of its SERENITY At-Home pivotal Phase 3 trial for the acute treatment of agitation associated with bipolar disorders or schizophrenia. The company expects topline data in the second half of 2025 to support a potential sNDA submission for label expansion of IGALMI® in the home setting.

GlobeNewswire Inc.
BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics announced a proposed public offering of common stock and warrants to fund clinical trials and general corporate purposes.

Benzinga
BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics, a biopharmaceutical company, announced a proposed public offering of common stock and warrants. The proceeds will be used to fund clinical trials and for general corporate purposes.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 20:25:03 UTC